HC Wainwright Analysts Boost Earnings Estimates for CorMedix

CorMedix Inc (NASDAQ:CRMD) – Stock analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for CorMedix in a research note issued on Thursday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $2.25 per share for the year, up from their previous forecast of $1.96. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2026 earnings at $2.77 EPS, FY2027 earnings at $2.30 EPS and FY2028 earnings at $2.25 EPS.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, October 8th. D Boral Capital upgraded CorMedix from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. JMP Securities reissued a “market outperform” rating and set a $22.00 price target on shares of CorMedix in a research report on Tuesday, September 9th. Zacks Research upgraded shares of CorMedix from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 4th. Finally, Needham & Company LLC cut their price objective on shares of CorMedix from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $18.33.

CorMedix Stock Up 0.9%

CorMedix stock opened at $10.07 on Monday. The business has a fifty day moving average of $11.27 and a two-hundred day moving average of $12.11. The firm has a market cap of $793.41 million, a P/E ratio of 13.43 and a beta of 1.80. CorMedix has a twelve month low of $5.60 and a twelve month high of $17.43.

CorMedix (NASDAQ:CRMD) last issued its earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.78. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.The business had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $65.63 million. During the same period in the prior year, the business earned ($0.05) EPS. The business’s revenue for the quarter was up 810.2% compared to the same quarter last year. CorMedix has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Insider Buying and Selling at CorMedix

In related news, insider Kaufman Beth Zelnick sold 50,000 shares of CorMedix stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $13.41, for a total value of $670,500.00. Following the completion of the sale, the insider directly owned 180,418 shares in the company, valued at $2,419,405.38. This trade represents a 21.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Myron Kaplan bought 25,000 shares of the company’s stock in a transaction on Thursday, October 23rd. The shares were bought at an average cost of $11.02 per share, for a total transaction of $275,500.00. Following the transaction, the director owned 201,034 shares in the company, valued at $2,215,394.68. The trade was a 14.20% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have sold 163,997 shares of company stock valued at $2,163,617. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On CorMedix

A number of large investors have recently made changes to their positions in the stock. Comerica Bank lifted its position in CorMedix by 454.6% during the 3rd quarter. Comerica Bank now owns 2,690 shares of the company’s stock worth $31,000 after acquiring an additional 2,205 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of CorMedix in the second quarter worth about $42,000. USA Financial Formulas purchased a new position in shares of CorMedix in the second quarter worth about $55,000. State of Alaska Department of Revenue acquired a new stake in shares of CorMedix during the third quarter worth about $54,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in CorMedix in the third quarter valued at approximately $55,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.